



CANADIAN ALLERGY & IMMUNOLOGY TODAY

SPECIAL
SUPPLEMENT

MAST CELLS IN ATOPIC DISEASES: MORE THAN JUST HISTAMINE

Theoharis C. Theoharides, MS MPhil MD PhD



Canadian Allergy & Immunology Today is published 3 times per year in English and French.


Our 2022 editorial board consists of:

VIPUL JAIN, MD

NIKHIL JOSHI, MD

JASON OHAYON, MD

SUSAN WASERMAN, MD



This supplement contains approved educational content affiliated with *Canadian Allergy & Immunology Today* and qualifies for Section 2 (self-learning) credits towards the maintenance of certification.

For information on how this activity fits in the Royal College Maintenance of Certification (MOC) Program, please visit the Royal College's website (royalcollege.ca/moc). For more personalized support, please contact the Royal College Services Centre (1-800-461-9598) or your local CPD Educator.

If you would like to contribute to a future issue of *Canadian Allergy & Immunology Today* please email us at info@catalytichealth.com

ABOUT THE AUTHOR

THEOHARIS C. THEOHARIDES
MS MPHIL MD PHD

Dr. Theoharides is Professor of Pharmacology and Internal Medicine, and Director of Molecular Immunopharmacology and Drug Discovery at Tufts University School of Medicine, Boston. He received his degrees (BA *cum laude*, MS, MPhil, PhD, MD) from Yale University and was awarded the *Winternitz Prize* in Pathology. He trained in internal medicine at New England Medical Center and received the Oliver Smith Award "*recognizing excellence, compassion and service.*" He received a Certificate in Global Leadership from the Tufts Fletcher School of Law and Diplomacy and a Fellowship at the Harvard Kennedy School of Government. He was awarded the *Distinguished Faculty Recognition Award* twice, the *Excellence in Teaching* ten times and the *Alumni Award for Faculty Excellence*. He first showed that mast cells, known for allergic reactions, are critical for neuroinflammatory conditions. He has published 470 scientific papers with over 40,000 citations and was listed in the world's top 2% most cited scientists. He has received 37 patents and trademarks. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences. He has been recognized with the *2018 Albert Nelson Marquis Lifetime Achievement* and the *Distinguished Humanitarian Awards*.



MAST CELLS IN ATOPIC DISEASES: MORE THAN JUST HISTAMINE

Abstract

Mast cells are present in all tissues and are able to release multiple mediators in response to allergic, autoimmune, environmental, neurohormonal and pathogenic triggers. Histamine has received most of the attention in terms of pathophysiology and drug development, while tryptase remains to this date with no clear function and no known inhibitor. Mast cells can also release pro-inflammatory and pruritogenic molecules, such as IL-6 and IL-31, selectively without degranulation. One such critical molecule is platelet activating factor (PAF), which is vasoactive, can cause wheal and flare on its own, but can also stimulate eosinophils and mast cells that are critical in the pathogenesis of chronic spontaneous urticaria (CSU) and rhinitis. Mast cell-derived cytokines and PAF have also been implicated in inflammatory processes including COVID-19. Among the second generation histamine-1 receptor antagonists, rupatadine is more effective overall, it has potent anti-PAF activity, and also inhibits activation of human mast cells and eosinophils. Rupatadine could, therefore, serve as a first-line drug for CSU and rhinitis, but may also be used, especially for patients resistant to antihistamines.

Biology of Mast Cells

Mast cells¹⁻⁵ derive from hematopoietic precursors,⁶ travel in the circulation as precursor cells and proliferate in response to stem cell factor (SCF), the ligand of the surface tyrosine kinase receptor CD117 (C-KIT).⁷ Mast cells mature and are located perivascularly⁸⁻¹⁰ in all tissues¹¹ under the influence of local micro-environmental factors^{12,40} resulting in different phenotypes.¹³ Mast cells are present in the brain,^{14,15} including the meninges,^{16,17} and the median eminence^{16,18,19} where they are located perivascularly in close proximity to neurons²⁰ that are positive for corticotropin releasing hormone (CRH).¹⁶ Brain mast cells are the richest source of histamine,²¹ which is involved in neurodevelopment.²² Furthermore, histamine

may serve as an alert signal in the brain when high attention or a strong wake-drive is needed, such as during exploration, learning and motivation.²³ Brain mast cells have been associated with memory consolidation and retrieval,²⁴⁻²⁶ as well as arousal^{27,28} and motivation.^{29,30}

Mast cells are typically activated by allergens crosslinking specific immunoglobulin E (IgE) bound to high affinity surface Fc epsilon receptor 1 (FcεRI).^{31,32} Even though mature mast cells reside in the tissues, they probe the blood vessel lumen by extending filopodia through endothelial gaps, capturing IgE from the circulation, and sensing circulating antigens.³³ Contrary to early research, fetal mast cells can bind maternal circulating IgE and contribute to postnatal allergic responses.³⁴ Quite surprisingly, prenatal stressful events have been reported to increase cord blood IgE.³⁵

Mast cells are also triggered by non-IgE stimuli³⁶⁻³⁸ and by additional ligands,³⁹ including neuropeptides,⁴⁰ such as CRH,⁴¹ neurotensin (NT),⁴² substance P (SP)⁴³ and somatostatin^{44,45} via high affinity receptors (**Table 1**), as well as by many cationic compounds through the low affinity G-coupled receptor MRGPRX2.⁴⁶ This process is distinct from that utilizing the FcεRI and may lead to release of different mediators. Allergic stimulation of mast cells leads to secretion of the SP-related peptide Hemokinin-1, which augments IgE-mediated allergic responses by binding with low affinity to the SP receptor (NK1) on mast cells.⁴⁷ CRH augmented release from human mast cells stimulated by IgE/anti-IgE of vascular endothelial growth factor (VEGF), which is also vasodilatory, could contribute to edema and has been shown to be increased in lesional skin in CSU.⁴⁸ Mast cells are also triggered by pathogens including fungi,⁴⁹ toxins,⁵⁰ as well as viruses^{51,52} including SARS-CoV-2.^{53,54} Mast cells express multiple receptors for a variety of stimuli (**Table 1**),^{40,55} including receptors for sex hormones.⁵⁶ In addition, mast cells can synthesize hormones⁵⁷ and neuropeptides such as CRH,⁵⁸ as well as the

Table 1. Main Mast Cell Receptors	
Receptor	Ligand
A2A, A2B, A3	Adenosine
ACTH-R	Adrenocorticotrophin
ACE2	Angiotensin 2
Beta2-Adrenoreceptor	Adrenaline
Cannabinoid CB2 receptor	2-arachidonoyl-glycerol, anandamide
C3a, C5a	Complement
C-kit (CD117)	Stem cell factor
CXCR1-4	Chemokines
CD47	Integrins
CD300	Eosinophilic Cationic proteins
CRHR-1, 2	CRH, urocortin
Estrogen receptors A,B	Estrogens
ETA, B	Endothelin-1
FcalphaR (CD89)	IgA
FcepsilonR	IgE
FcgammaRI, RIIA, RIIB, RIII	IgG
GABA-A, B, C	Benzodiazepines, gamma-aminobutyric
NMDAR, AMPAR, and kainate receptors	Glutamate
Heparan sulfate	Bacterial, viral antigens
H1, H2, H3	Histamine
IL-1R1	IL-1beta
IL-4R	IL-4, IL-13
IL-6R+IL6ST/GP130/IL6-beta	IL-6
IL-10R1,2	IL-10
IL-17R	IL-17
IL-18Ralpha+IL-18Rbeta	IL-18
LDL, VLDL	Apolipoprotein E
Mel1a, Mel1b, MT1, MT2	Melatonin
NGFR (CD271 or p75 neurotrophinR) neurotrophic factor	Nerve growth factor, brain-derived
MHCI, II	Antigenic peptides
MRGPRX2	Cationic peptides
NK-1	Substance P, emokinin-1
NT3	Neurotensin
Opioid receptors	Endorphins, encephalins
PAF-R	Platelet activating factor
PAR	Proteases
Progesterone receptor	Progestins
ST2	IL-33
TGFBR1,2 and 3	TGFbeta
TLR(1-9)	DAMPs, Pathogens
VDR	Vitamin D

peptide neurotensin (NT),⁵⁹ which can sensitize sensory nerve endings and mediate the effect of stress. Mast cells in the pineal and the hypothalamus may also be involved in circadian rhythms.⁶⁰⁻⁶³

Upon stimulation, mast cells rapidly secrete via degranulation multiple mediators that include the preformed, granule-stored such as heparin, histamine, tryptase and TNF.³ Histamine has been the main mediator associated with mast cells,^{64,65} but is also released from basophils.⁶⁶ Interestingly, mast cells can also generate a histamine-releasing peptide from albumin,⁶⁷ meaning that once stimulated mast cells can release enzymes that can act on albumin and produce a peptide that can further stimulate mast cells. Mast cells also secrete newly synthesized mediators 6-24 hours after stimulation (late-phase reaction); these include prostaglandin D₂ (PGD₂),⁶⁸ cytokines (IL-5, IL-6, IL-31, IL-33 and TNF) and chemokines (CCL2, CCL5 and CXCL8),^{4,5,69} as well as platelet activating factor (PAF),⁷⁰ which has been implicated in inflammation⁷¹ and microthromboses.^{71,72} PAF has many potent biological effects on almost all tissues and organs, leading to inflammation and microthromboses.⁷¹ PAF is the most potent trigger of platelet aggregation known. It was discovered in 1972.⁷³ Its structure was elucidated in 1979 by Demopoulos and colleagues as a glyceryl-ether lipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine).⁷⁴ PAF is produced by many prokaryotic and eukaryotic cells, but it is extremely short-lived making its routine measurement in biologic fluids difficult.⁷⁵

Selective release of mediators

Mast cells can release *specific* mediators, such as serotonin,⁷⁶ IL-6⁷⁷ and VEGF⁷⁸ without

degranulation, but rather via intragranular changes associated with release of mediators without release of histamine or tryptase.⁷⁹ In addition, the "alarmin" IL-33⁸⁰⁻⁸² stimulates mast cells via activation of its own specific surface receptor, ST2, significantly increasing the ability of SP to stimulate release of VEGF,^{43,83} IL-31,⁸⁴ TNF⁸⁵ and IL-1 β ,⁸⁶ as well as CCL2 and CCXL8⁸⁷ and other newly synthesized mediators.⁸² IL-33 also augments release of IL-31 from human mast cells stimulated either by SP or IgE/anti-IgE.⁸⁴ Mast cells can release IL-33, themselves.⁸⁸ Mast cell-derived IL-1 β or histamine-induced release of IL-1 β from macrophages⁸⁹ can then stimulate mast cells to release IL-6 selectively without degranulation.^{77,90} IL-6 is elevated in systemic mastocytosis and correlated with disease severity,⁹¹⁻⁹³ and is also elevated in COVID-19.^{94,95} In fact, IL-6 promotes an increase in mast cell numbers,⁹⁶ and is constitutively released in the presence of the D816V-KIT mutation.⁹⁷ IL-6 and other mast cell-derived molecules, such as bradykinin, IL-31, matrix metalloproteinase-9 (MMP-9) and PAF are quite pruritogenic (**Table 2**).

We had called brain mast cells the "immune gate to the brain"¹⁴ and the "immunoendocrine master player."⁹⁸ Restraint stress in rodents increased blood-brain barrier (BBB) permeability^{18,99,100} via CRH-stimulating mast cells.^{99,101,102} Mast cell-derived mediators, such as cytokines,^{103,104} increased BBB permeability not only to small molecules,^{18,99} but also to mammary adenocarcinoma brain metastases in mice.¹⁰¹ This process could worsen with stress, including psychological stress acting via CRH stimulation of mast cells^{99,101} leading to increased dura vascular permeability¹⁰⁵-- an effect that was absent in mast cell-deficient mice.¹⁰⁶ Allergic stimulation of nasal mast cells resulted in stimulation of the hypothalamic-

pituitary-adrenal (HPA) axis,^{41, 107-109} possibly via mast cell release of histamine,¹¹⁰ IL-6¹¹¹ and CRH.⁵⁸ The regulation of mast cells by neuropeptide and neurotransmitters was reviewed recently.^{40,112,113}

The mode and extent of mast cell responsiveness ultimately depends on the interplay between stimulatory and inhibitory signaling pathways. Mast cell responsiveness may be regulated not only by the neuroimmune stimuli, but also by the effects of the different receptors involved. For instance, mast cells express high affinity NK-1 receptors for SP.^{85,114} Moreover, SP¹¹⁵ and NT¹¹⁶ induced the expression of CRHR-1 in human mast cells. Secretion of mediators can occur utilizing different signaling¹¹⁷⁻¹²⁰ and secretory^{117,121} pathways. The diagnosis of atopic diseases rests on clinical symptoms and the measurement of a number of molecules in the blood and urine (**Table 3**). However, there are no specific mast cell markers;¹²² histamine is degraded within a few minutes, while tryptase reflects the mast cell volume rather than its activation. Moreover, mast cells are also implicated in both health and disease,^{38,123,120,124} especially immunity^{125,126} and inflammation.^{38,127,128}

Pathophysiology of Chronic Spontaneous Urticaria (CSU)

CSU is a common skin condition characterized by wheals and flares, but also intense itching, with or without angioedema^{129,130} and constitutes a major global health burden.¹³¹

Mast cells are a necessary component in the pathogenesis of CSU,¹³² but so are eosinophils.¹³³

CSU is a clinical diagnosis. In spite of proposals for potential blood biomarkers, to date there is no consensus of specific biomarkers for CSU.^{134,135} Elevations of

D-Dimer, eosinophil cationic protein (ECP), IL-6, matrix metalloproteinase-9 (MMP-9), PAF, TNF and vitamin D3 are the most useful markers for the diagnosis of CSU (**Table 4**). In addition, the presence of dermatographia and a positive anti-FcεRI IgG (basophil activation test) are commonly present in such patients (**Table 4**). Elevated mean serum IgE levels and blood eosinophils, along with the presence of positive skin prick tests to aeroallergens, correlates with the presence of anti-FcεRI IgG and anti-IgE IgG.¹³⁶ It was recently shown that elevated serum levels of the non-specific mast cell surface receptor MMRGPRX2 correlated with disease severity in CSU.¹³⁷ These findings may explain why as many as 30% of patients with CSU are resistant to antihistamines (**Table 4**).^{131,138}

Elevated PAF levels had been strongly associated with severe anaphylaxis,^{139,140} more so than histamine or tryptase.¹⁴¹ Moreover, combination treatment blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis.¹⁴² PAF is also reported to be involved in allergies in general,¹⁴³ and more specifically in allergic rhinitis,^{144,145} immediate and late cutaneous reactions,¹⁴⁶ as well as CSU.¹⁴⁷

With respect to allergic rhinitis,¹⁴⁵ PAF has been identified in nasal polyps and eosinophils,¹⁴⁴ and has been shown to stimulate eosinophils,^{148,149} especially superoxide ion generation.¹⁵⁰ More specifically, PAF is believed to be more potent than histamine in increasing nasal airway resistance.¹⁵¹ PAF appears to have a bidirectional association with cytokines. For instance, IL-6 stimulates production of PAF,^{152,153} while PAF induces IL-6 production.¹⁵⁴⁻¹⁵⁶ Elevated blood PAF levels have been reported in patients refractory to treatment with antihistamines.¹⁴⁷ Additionally, PAF-induced wheal and flare reactions on their own, are

Table 2. Pruritogenic Molecules Released From Mast Cells

• Adenosine
• Bradykinin
• LTC ₄
• Histamine
• IL-6
• IL-31
• MMP-9
• PAF
• PGD ₂
• Substance P (SP)
• TNF
• Tryptase

Table 3. Laboratory Tests for Diagnosis of Atopic Conditions

Blood
• IgE, IgG ₁ , IgG ₄
• Immune IgE (RAST for alpha-gal, casein, gluten, dust mites, fungi, grass, pollen)
• Anti-IgE receptor antibody (basophil activation test)
• CCL2, CXCL8 (IL-8)
• Food Intolerance Panel
• Heparin
• IL-4, IL-6, IL-31
• PGD ₂
• Tryptase
Urine 24 hours or first-morning void (must be kept and sent cold)
• LTE ₄
• N-Methylhistamine (NMH) or methylimidazole acetic acid (MIA)
• PGD ₂
• 2,3-Dinor-11β-PGF _{2a}

independent from histamine.¹⁵⁷ These findings indicate that PAF plays a major role in CSU by having a direct effect on the skin independent of histamine, but also stimulating mast cells to release other pruritogenic molecules.

A key aspect of CSU is pruritus.^{158, 159} As mentioned earlier, a number of mast cell-derived molecules are involved in pruritus (**Table 3**), especially IL-31,¹⁶⁰⁻¹⁶² which has been reported to be elevated in CSU.¹⁶³ Research has demonstrated that human mast cells can release IL-31 in response to allergic and non-allergic triggers, especially IL-33.⁸⁴ Unfortunately, IL-31 is not yet measured in clinical laboratories.

Pruritus in general,¹⁶⁴ and in CSU specifically,¹⁶⁵ worsens with stress. Pruritus is mediated by neuroimmune circuits,¹⁶⁶ especially the interactions between peripheral nerves, mast cells and eosinophils.¹⁶⁷ In this context, it may be relevant that PAF stimulates expression of histamine-1 receptors in trigeminal ganglia,¹⁶⁸ implying that it may have a similar action on cutaneous sensory nerves resulting in increased sensitivity to histamine.

Role of mast cells and PAF in COVID-19

The pathogenesis of most patients with COVID-19 is significant for the presence of perivascular inflammation and microthrombi¹⁶⁹⁻¹⁷¹ that could involve PAF.^{71,72,172} The mediators involved could be released from mast cells.^{72,89,173-177} Mast cell degranulation associated with interstitial edema and immunothrombosis has been reported in the alveolar septa of deceased patients with COVID-19.⁵⁴ In fact, mast cell-derived chymase was shown to be elevated in the serum of patients with COVID-19^{178,179} as have been eosinophil-related mediators.¹⁷⁹ Another study reported increased

1. Angioedema
2. Presence of Dermatographia
3. Anti-IgE IgG
4. Positive Anti-FcεRI IgG (basophil activation test)
5. Elevated serum levels of:
• D-Dimer (angioedema)
• Eosinophilic cationic protein (ECP)
• IgE
• IL-6
• IL-31
• Matrix Metalloproteinase-9 (MMP-9)
• MRGPRX2
• Platelet Activating Factor (PAF)
• TNF
6. Decreased Vitamin D3 (1,25-OH)

number of eosinophils in the blood of patients with COVID-19.¹⁸⁰ Interestingly, many COVID-19 patients also develop urticaria.^{181,72, 89,173-177}

Many patients (30-50%) infected with SARS-CoV-2 develop a post-acute syndrome a few months after the initial infection¹⁸²⁻¹⁸⁶ known as post-acute COVID or "long-COVID."^{183,187-189} Long COVID is particularly associated with persistent fatigue¹⁹⁰ and cognitive dysfunction, known as brain fog.^{183,188,189,191-197} Symptoms experienced by COVID patients, especially cognitive dysfunction,¹⁹⁸⁻²⁰⁰ are similar^{174,175} to those present in patients with mast cell activation syndrome (MCAS).^{201,202} Mast cells in such patients can be stimulated by environmental and stress triggers¹¹ and viruses⁵² including SARS-CoV-2.^{53,176,203}

Treatment approaches

There are still no clinically effective mast cell inhibitors.^{204, 205} A number of inhibitors of the tyrosine kinase c-kit receptor that block mast cell proliferation have been developed,^{206,207} but most of them do not inhibit mast cell activation.²⁰⁸ Disodium cromoglycate (cromolyn), known as a "mast cell stabilizer," had originally been shown to inhibit rat peritoneal mast cell histamine release.²⁰⁹ However, cromolyn does not effectively inhibit either murine mast cells²¹⁰ or human mast cells.²¹²⁻²¹⁴ The first generation histamine-1 receptor antagonist ketotifen has been promoted as a mast cell inhibitor, but the only such evidence is from a few studies using conjunctival mast cells, and it is very sedating. New approaches address new histamine receptors,²¹¹ such as the putative inhibitory receptor (Siglec-8).^{138,212,213}

Avoidance of potential triggers (**Table 5**) is self-evident.

Supplementation with the main histamine metabolizing enzyme, diamine oxidase²¹⁴ and Vitamin D3,²¹⁵ which has been shown to modulate immune responses²¹⁶ and suppresses the production of VEGF from mast cells in CSU²¹⁷ may be helpful.

The initial treatment approach is the use of second-generation, non-sedating histamine-1 receptor antagonists up to 4 times the recommended doses as tolerated (**Table 5**).^{129,218-221} One of these, the histamine-1 receptor antagonist rupatadine, was specifically developed to have potent anti-PAF activity.²²² The relative potency of rupatadine for blocking the histamine-1 receptor using histamine-induced guinea pig ileum contraction was shown to be about 24x greater than cetirizine and 75x greater than loratadine.²²³ Rupatadine at 40 mg/day is well tolerated and inhibits histamine- and PAF-induced flares and *ex vivo* platelet aggregation in normal male subjects.²²⁴ When compared to other non-sedating antihistamines in chronic urticaria, 20 mg/day of rupatadine showed the greatest efficacy in the treatment of CSU (71.6%) as compared to 80 mg/day of bilastine (60%), 20 mg/day of desloratadine (50%), 240 mg b.i.d. of fexofenadine (56%), and 20 mg/day of levocetirizine (21.7%).²²⁵ In a network meta-analysis comparing the efficacy of second-generation antihistamines in CSU, rupatadine was superior to other antihistamines including bilastine with respect to change from baseline in pruritus and wheal scores.²²⁶

Notably, rupatadine also inhibited histamine and TNF release from human mast cells in response to PAF,³⁶ and the release of histamine and IL-6 from human mast cells stimulated by different triggers.²²⁷ In another study comparing rupatadine to desloratadine and

Table 5. Histamine-1 Receptor Antagonists	
Drug	Characteristics
• Bilastine	Nonsedating
• Cetirizine	Nonsedating
• Levocetirizine	Nonsedating
• Cyproheptadine	Antiserotonergic
• Diphenhydramine	Sedating
• Hydroxyzine	Anxiolytic
• Ketotifen	Anti-eosinophilic
• Loratadine	Nonsedating
• Desloratadine	Nonsedating
• Mizolastine	Nonsedating
• Rupatadine	Nonsedating, anti-PAF, mast cell inhibitor
Tricyclic Antidepressants	
• Amitriptyline (Elavil)	Weight gain
• Doxepin	Also H2 receptor antagonist
Phenothiazines	
• Promethazine	Antiemetic
• Prochlorperazine	Antiemetic

levocetirizine, rupatadine was shown to be superior at inhibiting PAF-induced release of histamine from human mast cells.²²⁸

As discussed earlier, many patients with CSU do not respond to antihistamines (**Table 4**). For such patients, the anti-IgE omalizumab may be an appropriate treatment option.²²⁹

Conclusion

Mast cells have useful physiologic functions,²³¹ and play a critical role in atopic diseases,¹¹ especially allergies³⁸ and anaphylactic reactions,^{2,4,11,231} as well as inflammation.^{2,128,230,232,233} Given the multiple pathways involved in

CSU, the possession of potent anti-PAF, anti-eosinophilic and mast cell inhibitory properties by rupatadine, makes it an excellent first-line drug for this debilitating condition.

References:

- Csaba G. Mast cell, the peculiar member of the immune system: A homeostatic aspect. *Acta Microbiol Immunol Hung* 2015; 62(3):207-231.
- Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. *Ann N Y Acad Sci* 2006; 1088:78-99.
- Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. *Nat Rev Immunol* 2014; 14(7):478-494.
- Castells M. Mast cell mediators in allergic inflammation and mastocytosis. *Immunol Allergy Clin North Am* 2006; 26(3):465-485.
- Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. *Immunol Rev* 2018; 282(1):121-150.
- Chen CC, Grimaldeston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. *Proc Natl Acad Sci U S A* 2005; 102(32):11408-11413.
- Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets 1. *Immunity* 2012; 37(1):25-33.
- Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. *Science* 1996; 271:818-822.
- Kitamura Y, Ito A. Mast cell-committed progenitors. *Proc Natl Acad Sci U S A* 2005; 102(32):11129-11130.
- Schmetzer O, Valentin P, Church MK, Maurer M, Siebenhaar F. Murine and human mast cell progenitors. *Eur J Pharmacol* 2016; 778:2-10.
- Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. *N Engl J Med* 2015; 373(2):163-172.
- Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. *Nat Immunol* 2011; 12(11):1035-1044.
- Theoharides TC. Skin Mast Cells: Are We Missing the Forest for the Trees? *Exp Dermatol* 2016; 25(6):422-423.
- Theoharides TC. Mast cells: the immune gate to the brain. *Life Sci* 1990; 46:607-617.
- Traina G. Mast cells in the brain - Old cells, new target. *J Integr Neurosci* 2017; 16(s1):S69-S83.
- Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. *Brain Res* 1999; 849:1-15.
- Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC. Mast cells in meningiomas and brain inflammation. *J Neuroinflammation* 2015; 12(1):170.
- Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* 2007; 12:1615-1628.
- Colonna M, Butovsky O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. *Annu Rev Immunol* 2017; 35:441-468.
- Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. *Trends Immunol* 2006; 27(1):32-39.
- Panula P. Histamine receptors, agonists, and antagonists in health and disease. *Handb Clin Neurol* 2021; 180:377-387.
- Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A Review. *Front Neurosci* 2021; 15:680214.
- Mochizuki T. Histamine as an Alert Signal in the Brain. *Curr Top Behav Neurosci* 2021.
- Provensi G, Costa A, Izquierdo I, Blandina P, Passani MB. Brain histamine modulates recognition memory: possible implications in major cognitive disorders. *Br J Pharmacol* 2020; 177(3):539-556.
- Passani MB, Benetti F, Blandina P, Furini CRG, de Carvalho MJ, Izquierdo I. Histamine regulates memory consolidation. *Neurobiol Learn Mem* 2017; 145:1-6.
- Burgess CR. Histamine and orexin in the control of arousal, locomotion, and motivation. *J Neurosci* 2010; 30(8):2810-2811.
- Sadek B, Saad A, Sadeq A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. *Behav Brain Res* 2016; 312:415-430.
- Schlicker E, Kathmann M. Role of the Histamine H3 Receptor in the Central Nervous System. *Handb Exp Pharmacol* 2017; 241:277-299.
- Torrealba F, Riveros ME, Contreras M, Valdes JL. Histamine and motivation. *Front Syst Neurosci* 2012; 6:51.
- Nomura H, Shimizume R, Ikegaya Y. Histamine: A Key Neuromodulator of Memory Consolidation and Retrieval. *Curr Top Behav Neurosci* 2021.
- Rivera J, Fierro NA, Olivera A, Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. *Adv Immunol* 2008; 98:85-120.
- Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. *J Allergy Clin Immunol* 2006; 117(6):1214-1225.
- Cheng LE, Hartmann K, Roers A, Krummel MF, Locksley RM. Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E. *Immunity* 2013; 38(1):166-175.
- Msallam R, Balla J, Rathore APS et al. Fetal mast cells mediate postnatal allergic responses dependent on maternal IgE. *Science* 2020; 370(6519):941-950.
- Peters JL, Cohen S, Staudenmayer J, Hosen J, Platts-Mills TA, Wright RJ. Prenatal negative life events increases cord blood IgE: interactions with dust mite allergen and maternal atopy. *Allergy* 2012; 67(4):545-551.
- Theoharides TC. Danger Signals and Inflammation. *Clin Ther* 2016; 38(5):996-999.
- Redegeld FA, Yu Y, Kumari S, Charles N, Blank U. Non-IgE mediated mast cell activation. *Immunol Rev* 2018; 282(1):87-113.
- Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. *J Allergy Clin Immunol* 2018; 142(2):381-393.
- Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. *Front Immunol* 2012; 3:238.
- Theoharides TC. Neuroendocrinology of mast cells: Challenges and controversies. *Exp Dermatol* 2017; 26(9):751-759.
- Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci* 2004; 25(11):563-568.
- Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliadis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. *Proc Natl Acad Sci USA* 2006; 103:7759-7764.
- Theoharides TC, Zhang B, Kempuraj D et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci U S A* 2010; 107(9):4448-4453.
- Theoharides TC, Betchaku T, Douglas WW. Somatostatin-induced histamine secretion in mast cells; a comparison with known mast cell secretagogues. *J Biol Chem* 1990.
- Theoharides TC, Douglas WW. Mast cell histamine secretion in response to somatostatin analogues and other peptides. *J Biol Chem* 1990.
- McNeil BD, Pundir P, Meeker S et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 2015; 519(7542):237-241.
- Sumpter TL, Ho CH, Pleet AR et al. Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. *J Allergy Clin Immunol* 2015; 135(4):1019-1030.
- Kay AB, Ying S, Ardelean E et al. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. *Clin Exp Allergy* 2014; 44(8):1053-1060.
- Saluja R, Metz M, Maurer M. Role and relevance of mast cells in fungal infections. *Front Immunol* 2012; 3:146.

50. Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. *Clin Ther* 2018; 40(6):903-917.
51. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol* 2010; 10(6):440-452.
52. Marshall JS, Portales-Cervantes L, Leong E. Mast Cell Responses to Viruses and Pathogen Products. *Int J Mol Sci* 2019; 20(17):4241.
53. Theoharides TC. Potential Association of Mast Cells with COVID-19. *Ann Allergy Asthma Immunol* 2020; 126(3):217-218.
54. Motta Junior JDS, Miggiolaro AFRD, Nagashima S et al. Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis. *Front Immunol* 2020; 11:574862.
55. Theoharides TC, Stewart JM. Genitourinary mast cells and survival. *Transl Androl Urol* 2015; 4(5):579-586.
56. Pang X, Cotreau-Bibbo MM, Sant GR, Theoharides TC. Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. *Br J Urol* 1995; 75:154-161.
57. Csaba G, Kovacs P. Hormones in the nucleus of mast cells: confocal microscopic immunocytochemical observations. *Horm Metab Res* 2009; 41(8):621-625.
58. Kempuraj D, Papadopoulou NG, Lytinas M et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 2004; 145:43-48.
59. Grounds MD, Radley HG, GebSKI BL, Bogoyevitch MA, Shavlakadze T. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. *Clin Exp Pharmacol Physiol* 2008; 35(7):846-851.
60. Baumann A, Gonnenswein S, Bischoff SC et al. The circadian clock is functional in eosinophils and mast cells. *Immunology* 2013; 140(4):465-474.
61. Wang X, Reece SP, Van Scott MR, Brown JM. A circadian clock in murine bone marrow-derived mast cells modulates IgE-dependent activation in vitro. *Brain Behav Immun* 2011; 25(1):127-134.
62. Christ P, Sowa AS, Froy O, Lorentz A. The Circadian Clock Drives Mast Cell Functions in Allergic Reactions. *Front Immunol* 2018; 9:1526.
63. Pham L, Baiocchi L, Kennedy L et al. The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators. *J Pineal Res* 2021; 70(2):e12699.
64. Csaba G. Regulation of mast cell formation. *Studia Biolog Acad Scient Hung* 1972; 11:7-148.
65. Uvnas B. Histamine storage and release. *Fed Proc* 1974; 33:2172-2176.
66. Borriello F, Iannone R, Marone G. Histamine Release from Mast Cells and Basophils. *Handb Exp Pharmacol* 2017; 241:121-139.
67. Cochrane DE, Carraway RE, Feldberg RS, Boucher W, Gelfand JM. Stimulated rat mast cells generate histamine-releasing peptide from albumin. *Peptides* 1993; 14:117-123.
68. Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. *Immunol Rev* 2007; 217:168-185.
69. Varvara G, Tettamanti L, Gallenga CE et al. Stimulated mast cells release inflammatory cytokines: potential suppression and therapeutic aspects. *J Biol Regul Homeost Agents* 2018; 32(6):1355-1360.
70. Alevizos M, Karagkouni A, Vasiadi M et al. Rupatadine inhibits inflammatory mediator release from human LAD2 cultured mast cells stimulated by PAF. *Ann Allergy Asthma Immunol* 2013; 111(6):524-527.
71. Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. *Biofactors* 2020; 46(6):927-933.
72. Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, Microthromboses, and Platelet Activating Factor. *Clin Ther* 2020; 42(10):1850-1852.
73. Ashraf MA, Nookala V. *Biochemistry of Platelet Activating Factor*. 2021.
74. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). *J Biol Chem* 1979; 254(19):9355-9358.
75. Demopoulos CA, Andrikopoulos NK, Antonopoulou S. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. *Lipids* 1994; 29(4):305-309.
76. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. *Nature* 1982; 297:229-231.
77. Kandere-Grzybowska K, Letourneau R, Kempuraj D et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 2003; 171(9):4830-4836.
78. Cao J, Papadopoulou N, Kempuraj D et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 2005; 174(12):7665-7675.
79. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitos D. Differential release of mast cell mediators and the pathogenesis of inflammation. *Immunol Rev* 2007; 217:65-78.
80. Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. *J Immunol* 2011; 186(4):2523-2528.
81. Saluja R, Khan M, Church MK, Maurer M. The role of IL-33 and mast cells in allergy and inflammation. *Clin Transl Allergy* 2015; 5:33.
82. Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. *J Allergy Clin Immunol* 2019; 143:451.
83. Cristinziano L, Poto R, Criscuolo G et al. IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors. *Cells* 2021; 10(1).
84. Petra AI, Tsilioni I, Taracanova A, Katsarou-Katsari A, Theoharides TC. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. *Allergy Asthma Proc* 2018; 39(2):153-160.
85. Taracanova A, Alevizos M, Karagkouni A et al. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. *Proc Natl Acad Sci U S A* 2017; 114(20):E4002-E4009.
86. Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. *Proc Natl Acad Sci U S A* 2018; 115(40):E9381-E9390.
87. Bawazeer MA, Theoharides TC. IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-kappaB, inhibited by methoxyluteolin. *Eur J Pharmacol* 2019; 865:172760.
88. Brown MA. *Studies of Mast Cells: Adventures in Serendipity*. *Front Immunol* 2018; 9:520.
89. Conti P, Caraffa A, Tete G et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. *J Biol Regul Homeost Agents* 2020; 34(5):1629-1632.
90. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ. Differential release of mast cell interleukin-6 via c-kit. *Blood* 1997; 89:2654-2663.
91. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* 2002; 128:344-350.
92. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. *Clin Immunol* 2005; 115(2):216-223.

93. Mayado A, Teodosio C, Garcia-Montero AC et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. *Leukemia* 2015; 30(1):124-130.
94. Herold T, Jurinovic V, Arnreich C et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol* 2020; 146(1):128-136.
95. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin Immunol* 2020; 146(3):518-534.
96. Kaur D, Gomez E, Doe C et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. *Allergy* 2015; 70(5):556-567.
97. Tobio A, Bandara G, Morris DA et al. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. *Haematologica* 2020; 105(1):124-135.
98. Theoharides TC. Mast cell: a neuroimmunoendocrine master player. *Int J Tissue React* 1996; 18(1):1-21.
99. Esposito P, Chandler N, Kandere-Grzybowska K et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* 2002; 303:1061-1066.
100. Fiorentino M, Sapone A, Senger S et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Mol Autism* 2016; 7:49.
101. Rozniecki JJ, Sahagian GG, Kempuraj D et al. Brain metastases of mouse mammary adenocarcinoma is increased by acute stress. *Brain Res* 2010; 1366:204-210.
102. Theoharides TC, Rozniecki JJ, Sahagian G et al. Impact of stress and mast cells on brain metastases. *J Neuroimmunol* 2008; 205(1-2):1-7.
103. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. *Cell Mol Neurobiol* 2000; 20:131-147.
104. Pan W, Stone KP, Hsueh H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. *Curr Pharm Des* 2011; 17(33):3729-3740.
105. Theoharides TC. Effect of psychological stress on mast cells. *Annals Allergy, Asthma, Immunology* 125[4], 388-392. 8-10-2020. Ref Type: Generic
106. Kandere-Grzybowska K, Gheorghie D, Priller J et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice 1. *Brain Res* 2003; 980(2):213-220.
107. Matsumoto I, Inoue Y, Shimada T, Aikawa T. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. *J Exp Med* 2001; 194:71-78.
108. Bugajski AJ, Chlap Z, Gadek-Michalska A, Borycz J, Bugajski J. Degranulation and decrease in histamine levels of thalamic mast cells coincides with corticosterone secretion induced by compound 48/80. *Inflamm Res* 1995; 44 Suppl 1:S50-S51.
109. Kalogeromitros D, Syrigou EI, Makris M et al. Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis. *Annals Allergy, Asthma, Immunology* 2007; 98:269-273.
110. Scaccianoce S, Lombardo K, Nicolai R, Affricano D, Angelucci L. Studies on the involvement of histamine in the hypothalamic-pituitary-adrenal axis activation induced by nerve growth factor. *Life Sci* 2000; 67:3143-3152.
111. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J Clin Endocrinol Metab* 1993; 77:1690-1694.
112. Theoharides TC, Tsilioni I, Bawazeer M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. *Front Cell Neurosci* 2019; 13:353.
113. Xu H, Shi X, Li X et al. Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review. *J Neuroinflammation* 2020; 17(1):356.
114. Okada T, Hirayama Y, Kishi S, Miyayasu K, Hiroi J, Fujii T. Functional neurokinin NK-1 receptor expression in rat peritoneal mast cells. *Inflamm Res* 1999; 48:274-279.
115. Asadi S, Alysandratos KD, Angelidou A et al. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. *J Invest Dermatol* 2012; 132(2):324-329.
116. Alysandratos KD, Asadi S, Angelidou A et al. Neurotensin and CRH interactions augment human mast cell activation. *PLoS One* 2012; 7(11):e48934.
117. Xu H, Bin NR, Sugita S. Diverse exocytic pathways for mast cell mediators. *Biochem Soc Trans* 2018; 46(2):235-247.
118. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. *Nat Rev Immunol* 2006; 6(3):218-230.
119. Gaudenzio N, Sibilano R, Marichal T et al. Different activation signals induce distinct mast cell degranulation strategies. *J Clin Invest* 2016; 126(10):3981-3998.
120. Sibilano R, Frossi B, Pucillo CE. Mast cell activation: a complex interplay of positive and negative signaling pathways. *Eur J Immunol* 2014; 44(9):2558-2566.
121. Crivellato E, Nico B, Gallo VP, Ribatti D. Cell secretion mediated by granule-associated vesicle transport: a glimpse at evolution. *Anat Rec (Hoboken)* 2010; 293(7):1115-1124.
122. Ogulur I, Pat Y, Ardicli O et al. Advances and highlights in biomarkers of allergic diseases. *Allergy* 2021.
123. Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. Mast Cells as Drivers of Disease and Therapeutic Targets. *Trends Immunol* 2018; 39(2):151-162.
124. Gallenga CE, Pandolfi F, Caraffa A et al. Interleukin-1 family cytokines and mast cells: activation and inhibition. *J Biol Regul Homeost Agents* 2019; 33(1):1-6.
125. Marone G, Galli SJ, Kitamura Y. Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. *Trends Immunol* 2002; 23:425-427.
126. Galli SJ, Grimbaldston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nat Rev Immunol* 2008; 8(6):478-486.
127. Hakim-Rad K, Metz M, Maurer M. Mast cells: makers and breakers of allergic inflammation. *Curr Opin Allergy Clin Immunol* 2009; 9(5):427-430.
128. Theoharides TC, Alysandratos KD, Angelidou A et al. Mast cells and inflammation. *Biochim Biophys Acta* 2012; 1822(1):21-33.
129. He L, Yi W, Huang X, Long H, Lu Q. Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management. *Clin Rev Allergy Immunol* 2021.
130. Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and Angioedema Across the Ages. *J Allergy Clin Immunol Pract* 2020; 8(6):1866-1874.
131. Goncalo M, Gimenez-Arnau A, Al-Ahmad M et al. The global burden of chronic urticaria for the patient and society. *Br J Dermatol* 2021; 184(2):226-236.
132. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. *Immunol Rev* 2018; 282(1):232-247.
133. Altrichter S, Frischbutter S, Fok JS et al. The role of eosinophils in chronic spontaneous urticaria. *J Allergy Clin Immunol* 2020; 145(6):1510-1516.
134. Kolkhir P, Andre F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. *Clin Exp Allergy* 2017; 47(1):19-36.
135. Deza G, Ricketti PA, Gimenez-Arnau AM, Casale TB. Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria. *J Allergy Clin Immunol Pract* 2018; 6(4):1108-1117.
136. Wong MM, Keith PK. Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review. *Allergy Asthma Clin Immunol* 2020; 16:72.
137. Cao TBT, Cha HY, Yang EM, Ye YM. Elevated MRGPRX2 Levels Related to Disease Severity in Patients With Chronic Spontaneous Urticaria. *Allergy Asthma Immunol Res* 2021; 13(3):498-506.

138. Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. *Nat Rev Immunol* 2021.
139. Vadas P, Gold M, Perelman B et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. *N Engl J Med* 2008; 358(1):28-35.
140. Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. *J Allergy Clin Immunol* 2015; 135(6):1424-1432.
141. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol* 2013; 131(1):144-149.
142. Arias K, Baig M, Colangelo M et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. *J Allergy Clin Immunol* 2009; 124(2):307-14, 314.
143. Palgan K, Bartuzi Z. Platelet activating factor in allergies. *Int J Immunopathol Pharmacol* 2015; 28(4):584-589.
144. Furukawa M, Ogura M, Tsutsumi T, Tsuji H, Yamashita T. Presence of platelet-activating factor in nasal polyps and eosinophils. *Acta Otolaryngol* 2002; 122(8):872-876.
145. Munoz-Cano RM, Casas-Saucedo R, Valero SA, Bobolea I, Ribo P, Mullol J. Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications. *J Clin Med* 2019; 8(9).
146. Rihoux JP, Fadel R, Juhlin L. Platelet-activating factor-induced immediate and late cutaneous reactions. *Int Arch Allergy Appl Immunol* 1991; 94(1-4):299-300.
147. Ulambayar B, Yang EM, Cha HY, Shin YS, Park HS, Ye YM. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study. *Clin Transl Allergy* 2019; 9:33.
148. Tedeschi A, Palumbo G, Milazzo N, Miadonna A. Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. *J Allergy Clin Immunol* 1994; 93(2):526-533.
149. Kato M, Kita H, Tachibana A, Hayashi Y, Tsuchida Y, Kimura H. Dual signaling and effector pathways mediate human eosinophil activation by platelet-activating factor. *Int Arch Allergy Immunol* 2004; 134 Suppl 1:37-43.
150. Zoratti EM, Sedgwick JB, Vrtis RR, Busse WW. The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophils. *J Allergy Clin Immunol* 1991; 88(5):749-758.
151. Austin CE, Foreman JC. The effect of platelet-activating factor on the responsiveness of the human nasal airway. *Br J Pharmacol* 1993; 110(1):113-118.
152. Gutierrez S, Palacios I, Egido J et al. IL-1 beta and IL-6 stimulate the production of platelet-activating factor (PAF) by cultured rabbit synovial cells. *Clin Exp Immunol* 1995; 99(3):364-368.
153. Biffi WL, Moore EE, Moore FA, Barnett CC, Jr., Silliman CC, Peterson VM. Interleukin-6 stimulates neutrophil production of platelet-activating factor. *J Leukoc Biol* 1996; 59(4):569-574.
154. Thivierge M, Rola-Pleszczynski M. Platelet-activating factor enhances interleukin-6 production by alveolar macrophages. *J Allergy Clin Immunol* 1992; 90(5):796-802.
155. Keglowich L, Baraket M, Tamm M, Borger P. Hypoxia exerts dualistic effects on inflammatory and proliferative responses of healthy and asthmatic primary human bronchial smooth muscle cells. *PLoS ONE* 2014; 9(2):e89875.
156. Hamel-Cote G, Lapointe F, Veronneau S, Mayhew M, Rola-Pleszczynski M, Stankova J. Regulation of platelet-activating factor-mediated interleukin-6 promoter activation by the 48 kDa but not the 45 kDa isoform of protein tyrosine phosphatase non-receptor type 2. *Cell Biosci* 2019; 9:51.
157. Krause K, Gimenez-Arnau A, Martinez-Escala E et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. *Allergy* 2013; 68(2):256-258.
158. Saini SS, Kaplan AP. Chronic Spontaneous Urticaria: The Devil's Itch. *J Allergy Clin Immunol Pract* 2018; 6(4):1097-1106.
159. Kim HJ. Pruritus in autoimmune connective tissue diseases. *Ann Transl Med* 2021; 9(5):441.
160. Gibbs BF, Patsinakidis N, Raap U. Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases. *Front Immunol* 2019; 10:1383.
161. Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: The "itchy" cytokine in inflammation and therapy. *Allergy* 2021; 76(10):2982-2997.
162. Murdaca G, Greco M, Tonacci A et al. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. *Int J Mol Sci* 2019; 20(23).
163. Chaowattanapanit S, Choonhakarn C, Salao K et al. Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms. *Heliyon* 2020; 6(12):e05621.
164. Golpanian RS, Kim HS, Yosipovitch G. Effects of Stress on Itch. *Clin Ther* 2020; 42(5):745-756.
165. Huang Y, Xiao Y, Jing D et al. Association of Chronic Spontaneous Urticaria With Anxiety and Depression in Adolescents: A Mediation Analysis. *Front Psychiatry* 2021; 12:655802.
166. Ayasse MT, Buddenkotte J, Alam M, Steinhoff M. Role of neuroimmune circuits and pruritus in psoriasis. *Exp Dermatol* 2020; 29(4):414-426.
167. Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. *Exp Dermatol* 2019; 28(12):1405-1411.
168. Nakasaki T, Masuyama K, Fukui H et al. Effects of PAF on histamine H1 receptor mRNA expression in rat trigeminal ganglia. *Prostaglandins Other Lipid Mediat* 1999; 58(1):29-41.
169. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020; 383(2):120-128.
170. Calabretta E, Moraleda JM, Iacobelli M et al. COVID-19-induced endothelitis: emerging evidence and possible therapeutic strategies. *Br J Haematol* 2021; 193(1):43-51.
171. Wang J, Doran J. The Many Faces of Cytokine Release Syndrome-Related Coagulopathy. *Clin Hematol Int* 2021; 3(1):3-12.
172. Klein M, Dao V, Khan F. A Review of Platelet-Activating Factor As a Potential Contributor to Morbidity and Mortality Associated with Severe COVID-19. *Clin Appl Thromb Hemost* 2021; 27:10760296211051764.
173. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. *Biofactors* 2020; 46(3):306-308.
174. Theoharides TC, Conti P. COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome? *J Biol Regul Homeost Agents* 2020; 34(5):1633-1636.
175. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020; 100:327-332.
176. Hafezi B, Chan L, Knapp JP et al. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. *Cells* 2021; 10(7).
177. Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Mast cells: Therapeutic targets for COVID-19 and beyond. *IUBMB Life* 2021; 73(11):1278-1292.
178. Tan J, Anderson DE, Rathore APS et al. Signatures of mast cell activation are associated with severe COVID-19. *medRxiv* 2021.
179. Gebremeskel S, Schanin J, Coyle KM et al. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. *Front Immunol* 2021; 12:650331.
180. Rodriguez L, Pekkarinen PT, Lakshmikanth T et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. *Cell Rep Med* 2020; 1(5):100078.
181. Algaadi SA. Urticaria and COVID-19: A review. *Dermatol Ther* 2020; 33(6):e14290.
182. Moreno-Perez O, Merino E, Leon-Ramirez JM et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. *J Infect* 2021; 82(3):378-383.

183. Nalbandian A, Sehgal K, Gupta A et al. Post-acute COVID-19 syndrome. *Nat Med* 2021; 27(4):601-615.
184. Montagne A, Nacion DA, Sagare AP et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. *Nature* 2020; 581(7806):71-76.
185. Sudre CH, Murray B, Varsavsky T et al. Attributes and predictors of long COVID. *Nat Med* 2021; 27(4):626-631.
186. Dennis A, Wamil M, Alberts J et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open* 2021; 11(3):e048391.
187. Baig AM. Chronic COVID Syndrome: Need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. *J Med Virol* 2020.
188. Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. *Crit Rev Clin Lab Sci* 2020;1-23.
189. Huang C, Huang L, Wang Y et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; 397(10270):220-232.
190. de Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugh TS, Seshadri S. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. *Alzheimers Dement* 2021; 17(6):1056-1065.
191. Baig AM. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome. *ACS Chem Neurosci* 2020; 11(24):4017-4020.
192. Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. *Biofactors* 2021; 47(2):232-241.
193. Graham EL, Clark JR, Orban ZS et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol* 2021; 8(5):1073-1085.
194. Stefano GB, Buttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis. *Med Sci Monit* 2021; 27:e933015.
195. Bell ML, Catalfamo CJ, Farland LV et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. *PLoS ONE* 2021; 16(8):e0254347.
196. Hugon J, Msika EF, Queneau M, Farid K, Paquet C. Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. *J Neurol* 2021; Jun 18:1-3.
197. sadi-Pooya AA, Akbari A, Emami A et al. Long COVID syndrome-associated brain fog. *J Med Virol* 2021.
198. Zhang X, Dong H, Li N et al. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis 1. *J Neuroinflammation* 2016; 13(1):127.
199. Moura DS, Sultan S, Georgin-Lavialle S et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. *PLoS ONE* 2012; 7(6):e39468.
200. Afrin LB, Pohlau D, Raithel M et al. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. *Brain Behav Immun* 2015; 50:314-321.
201. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. *J Allergy Clin Immunol* 2010; 126(6):1099-104.
202. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? *Expert Rev Clin Immunol* 2019; 15(6):639-656.
203. Motta Junior JDS, Miggiolaro AFRD, Nagashima S et al. Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis. *Front Immunol* 2020; 11:574862.
204. Theoharides TC, Alysandratos KD, Angelidou A et al. Mast cells and inflammation. *Biochim Biophys Acta* 2012; 1822(1):21-33.
205. Finn DF, Walsh JJ. Twenty-first century mast cell stabilizers 1. *Br J Pharmacol* 2013; 170(1):23-37.
206. Caslin HL, Kiwanuka KN, Haque TT et al. Controlling Mast Cell Activation and Homeostasis: Work Influenced by Bill Paul That Continues Today. *Front Immunol* 2018; 9:868.
207. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor 1. *Blood* 2000; 96(3):925-932.
208. Gotlib J, Kluin-Nelemans HC, George TI et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. *N Engl J Med* 2016; 374(26):2530-2541.
209. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 1980; 207(4426):80-82.
210. Oka T, Kalesnikoff J, Starkl P, Tsai M, Galli SJ. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. *Lab Invest* 2012; 92(10):1472-1482.
211. Thangam EB, Jemima EA, Singh H et al. The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. *Front Immunol* 2018; 9:1873.
212. Duguay BA, Lu L, Arizmendi N, Unsworth LD, Kulka M. The Possible Uses and Challenges of Nanomaterials in Mast Cell Research. *J Immunol* 2020; 204(8):2021-2032.
213. Duan S, Arlian BM, Nycholat CM et al. Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcepsilonRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge. *J Immunol* 2021; 206(10):2290-2300.
214. Podder I, Jaiswal S, Das A. Dietary strategies for chronic spontaneous urticaria: an evidence-based review. *Int J Dermatol* 2021.
215. Li Y, Cao Z, Guo J, Li Q, Su J. Effects of Serum Vitamin D Levels and Vitamin D Supplementation on Urticaria: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* 2021; 18(9).
216. Theoharides TC. Vitamin D and Atopy. *Clin Ther* 2017; 39(5):880-883.
217. Zhao JW, Ping JD, Wang YF et al. Vitamin D suppress the production of vascular endothelial growth factor in mast cell by inhibiting PI3K/Akt/p38 MAPK/HIF-1alpha pathway in chronic spontaneous urticaria. *Clin Immunol* 2020; 215:108444.
218. Shi Y, Zhou S, Zheng Q et al. Systematic reviews of pharmacological and nonpharmacological treatments for patients with chronic urticaria: An umbrella systematic review. *Medicine (Baltimore)* 2019; 98(20):e15711.
219. Yanai K, Yoshikawa T, Church MK. Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases. *Curr Top Behav Neurosci* 2021.
220. Iriarte SP, Armisen M, Usero-Barcena T et al. Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature. *J Investig Allergol Clin Immunol* 2021; 31(4):282-291.
221. Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the up dosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. *Pediatr Allergy Immunol* 2021; 32(1):153-160.
222. Gonzalez-Nunez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. *Expert Opin Drug Saf* 2016; 15(10):1439-1448.
223. Merlos M, Giral M, Balsa D et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). *J Pharmacol Exp Ther* 1997; 280(1):114-121.
224. Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. *Br J Dermatol* 2010; 163(6):1330-1332.

225. Sanchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Yanez A. Comparative efficacy of non-sedating antihistamine up dosing in patients with chronic urticaria. *World Allergy Organ J* 2014; 7(1):33.
226. Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis. *J Allergy Clin Immunol Pract* 2021; 9(2):956-970.
227. Vasiadi M, Kalogeromitros D, Kempuraj D et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. *Int Arch Allergy Immunol* 2010; 151(1):38-45.
228. Munoz-Cano R, insua-Enrich E, Torres-Atencio I et al. Effects of Rupatadine on Platelet-Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). *J Investig Allergol Clin Immunol* 2017; 27(3):161-168.
229. Agache I, Rocha C, Pereira A et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. *Allergy* 2021; 76(1):59-70.
230. Amin K. The role of mast cells in allergic inflammation. *Respir Med* 2012; 106(1):9-14.
231. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. *Immunol Allergy Clin North Am* 2006; 26(3):407-425.
232. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 2004; 146(1-2):1-12.
233. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. *Nature* 2008; 454(7203):445-454.



CANADIAN ALLERGY & IMMUNOLOGY TODAY

TO REGISTER FOR AND
RECEIVE FUTURE ISSUES, PLEASE VISIT
CANADIANALLERGYANDIMMUNOLOGYTODAY.CA

SPECIAL
SUPPLEMENT